Abstract
Numerous studies implicate the prolyl peptidase, fibroblast activation protein (FAP) in tumorigenesis; however, FAP-selective inhibitors have not yet been developed to fully validate FAP as a therapeutic target. Herein, we review recent efforts aimed at validating and inhibiting FAP for cancer therapy and highlight future directions for successful targeting of this prolyl peptidase.
MeSH terms
-
Antigens, Neoplasm / chemistry
-
Antigens, Neoplasm / metabolism
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Biomarkers, Tumor / antagonists & inhibitors*
-
Biomarkers, Tumor / chemistry
-
Biomarkers, Tumor / metabolism
-
Endopeptidases
-
Gelatinases
-
Humans
-
Membrane Proteins
-
Neoplasms / enzymology
-
Serine Endopeptidases / chemistry
-
Serine Endopeptidases / metabolism
-
Substrate Specificity
Substances
-
Antigens, Neoplasm
-
Antineoplastic Agents
-
Biomarkers, Tumor
-
Membrane Proteins
-
Endopeptidases
-
Serine Endopeptidases
-
fibroblast activation protein alpha
-
Gelatinases